Respiratory Syncytial Virus (RSV) – Forecast in Asia-Pacific Markets to 2028
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Pneumoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease. The most common clinical scenario for RSV is an upper respiratory tract infection which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which can progress to respiratory failure or death in rare occasions. RSV is also an important cause of hospitalizations and deaths in elderly adults.
The burden of RSV-associated illness is well known; however, challenges stemming from both product and clinical trial design have resulted in several high-profile product failures across all classes of agents including antivirals and prophylactic vaccines and antibodies. Further, the RSV market is limited in scope as the only approved prophylactic antibody, AbbVie and AstraZeneca’s Synagis (palivizumab), is recommended for a more narrow population than the antibody is labeled for (i.e., pediatric patients at increased risk of hospitalization due to RSV), and it is not licensed in either India or urban China. These difficulties have limited options for patients currently at risk for complications due to RSV; however, they have driven strong developer interest in addressing RSV across multiple therapeutic avenues.
Key Questions Answered
How will the RSV therapeutic market landscape in the 5GM (India, urban China, Australia, South Korea and Japan) change from 2018–2028?
What are the most promising late-stage pipeline drugs for RSV?
How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options?
What are the remaining unmet needs in RSV treatment management?
What drivers and barriers will affect RSV therapeutics sales in the 5GM over the forecast period?
Scope
Overview of RSV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
Topline RSV market revenue from 2018–2028. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
Key topics covered include current treatment and prophylactic options, unmet needs and opportunities, and the drivers and barriers affecting RSV therapeutics sales in the 5GM.
Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
Analysis of the current and future market competition in the global RSV therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Key Highlights
During the 10-year forecast period, there are 14 products that are on track to launch, contributing to a forecast growth in the 5GM from $37.19M in 2018 to $1.48B in 2028, which represents a CAGR of 44.7%.
The market in the 5GM in 2018 consists of a single monoclonal antibody product, AstraZeneca/AbbVie’s Synagis (palivizumab). As Synagis is not licensed in India or urban China, these markets do not contribute to total sales in the baseline year. The launch of AstraZeneca's prophylactic monoclonal antibody MEDI8897 in Australia, South Korea and Japan (2024), India (2025) and urban China (2026) will be a key driver of growth, replacing Synagis as standard of care prophylaxis for high risk infants. The launch of several vaccines for both adult and pediatric patients, such as Janssen's Ad26.RSV.preF and GlaxoSmithKline's GSK3844766A, will fulfill a major unmet need, and will have a significant effect on the overall size of the RSV prophylactics market. The Japan market has the highest base year sales, however, due to its large patient population urban China will have the highest sales in 2028.
Reasons to Buy
The report will enable you to:
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Asia-Pacific RSV market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the RSV therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
AstraZeneca
Bavarian Nordic
Enanta Pharmaceuticals
GlaxoSmithKline
Janssen
Merck & Co.
Novavax
Pfizer
Pulmocide
ReViral
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.